Skip to content
FIND A HEALTH VALLEY ACTOR

Cytiva opens a new production site in Grens (VD)

Cityva 3D

Cytiva opens its new 7,400 m2 production facility in Grens, Switzerland, on 31 May 2022.   The site will manufacture single-use kits for the Sepax and Sefia cell processing systems, as well as consumables for the Xuri cell expansion systems. The new site will be home to 250 employees and house the Centre of Excellence…

Read More

Votes are open for the TOP 100 Swiss Startups! 

Top Swiss Startups

What is your favorite swiss startup?   Every year the TOP 100 Swiss Startup Award showcases the 100 most innovative and promising Swiss startups. 438 Swiss deeptech startups have been featured in the ranking over the past decade. So far, they have created 11100 jobs and raised CHF 6.1 billion. In 2022, 269 Life Sciences…

Read More

Pr. Antoine Geissbuhler is the new BioAlps’ President

Prof. Antoine Geissbuhler BioAlps President

A Digital Health specialist to promote the Swiss Health Valley and the number one and most diversified Life Sciences Cluster in Europe   After a selection process of several months, BioAlps’ Executive Committee identified a strong candidate to take over the role of Mr Claude Clément as President of the BioAlps Association. On Thursday 19…

Read More

Alithea Genomics closes a CHF 1 million seed round

Alithea Genomics

Alithea Genomics, a Lausanne-based fast-growing, emerging leader in the field of RNA sequencing and transcriptomics analysis, announced the closing of a CHF 1 million seed financing round led by the Novalis Biotech Acceleration fund, with the participation of Swiss-based private investors.   Alithea has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation…

Read More

Dr. Andrea Pfeifer received the Aenne Burda Award

Dr. Andrea Pfeifer Ac Immune SA

The CEO and Director of AC Immune SA was recognized for her work to find treatments for Alzheimer’s disease   AC Immune SA (NASDAQ: ACIU), a Lausanne-based clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, was awarded the prestigious Aenne Burda Award…

Read More

Kodiak Sciences and Lonza open a new facility in Visp

Kodiak Sciences and Lonza open a new facility in Visp

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat retinal diseases, and Lonza announced on 17 May 2022 the opening of a new, custom-built, bioconjugation facility within Lonza’s Ibex® Dedicate manufacturing complex in Visp, Switzerland.   The facility will play a key role in the scaled…

Read More

SpArk, the centre for movement science and technologies, is born!

Spark centre for movement science and technologies

This new centre, dedicated to sport and performance, is the result of collaboration between the City of Sion and The Ark Foundation.   Officially launched on Thursday 19 May, SpArk aims to exploit the potential of digitalisation in health, sport and performance. The new cluster aims to be a driving force for economic development, by…

Read More

Hansjörg Wyss, the life sciences philanthropist

Hansjorg Wyss

On 17 May 2022, Hansjörg Wyss received the Gallatin Award from the Swiss American Chamber of Commerce for his great commitment to the science landscape in Switzerland.   “The ongoing commitment of Hansjörg Wyss and his Foundation to support groundbreaking research in Switzerland and elsewhere is more than a gift: it is a strong symbol…

Read More

ONWARD’s Neurostimulator Restores Mobility for Patients with Spinal Cord Injury

Onward 1

This is the first time the ARCIM is used on a human patient. This implantable pulse generator (IPG) stimulates the spinal cord to restore movement and autonomic functions for people with spinal cord injury and other conditions that affect mobility.   This first implant on a human patient is a major milestone in ONWARD’s successful…

Read More

HemostOD creates ex vivo blood platelets

HemostOD

HemostOD has developed a solution for ex vivo on-demand production of blood platelets. The company just received a CHF 100 000 Tech Seed loan from the Foundation for Technological Innovation (FIT). Worldwide, 10 million platelet concentrates are transfused each year. Platelets are small blood cells whose function is to stop bleeding. Today, patients can only…

Read More